Abstract
Current pharmacologic interventions in lipid metabolism are insufficient in a subset of patients at increased risk of cardiovascular disease. In particular, several monogenetic disorders of lipid metabolism with diverse clinical complications are beyond treatment to date. Somatic gene transfer is a potential approach to treat these disorders. This review describes the efforts made thus far to develop gene therapy for 3 major classes of dyslipidemia: Increased levels of lowdensity lipoprotein cholesterol, reduced levels of high-density lipoprotein cholesterol and increased plasma triglyceride levels. For many of the genetic causes underlying these conditions, proof-of-principle studies have been performed and in combination with improved vectors some of these strategies may be feasible for clinical use in the future.
Keywords: LDL, HDL, Triglycerides, Familial hypercholesterolemia, Apolipoprotein AI, Lipoprotein lipase, (helperdependent) Adenovirus, Adeno-associated virus
Current Gene Therapy
Title: Gene Therapy in Disorders of Lipoprotein Metabolism
Volume: 7 Issue: 1
Author(s): Stefan F.C. Vaessen, Jaap Twisk, John J.P. Kastelein and Jan Albert Kuivenhoven
Affiliation:
Keywords: LDL, HDL, Triglycerides, Familial hypercholesterolemia, Apolipoprotein AI, Lipoprotein lipase, (helperdependent) Adenovirus, Adeno-associated virus
Abstract: Current pharmacologic interventions in lipid metabolism are insufficient in a subset of patients at increased risk of cardiovascular disease. In particular, several monogenetic disorders of lipid metabolism with diverse clinical complications are beyond treatment to date. Somatic gene transfer is a potential approach to treat these disorders. This review describes the efforts made thus far to develop gene therapy for 3 major classes of dyslipidemia: Increased levels of lowdensity lipoprotein cholesterol, reduced levels of high-density lipoprotein cholesterol and increased plasma triglyceride levels. For many of the genetic causes underlying these conditions, proof-of-principle studies have been performed and in combination with improved vectors some of these strategies may be feasible for clinical use in the future.
Export Options
About this article
Cite this article as:
Vaessen F.C. Stefan, Twisk Jaap, Kastelein J.P. John and Kuivenhoven Jan Albert, Gene Therapy in Disorders of Lipoprotein Metabolism, Current Gene Therapy 2007; 7 (1) . https://dx.doi.org/10.2174/156652307779940261
DOI https://dx.doi.org/10.2174/156652307779940261 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry Different Patterns of Statin Use in Patients with Acute Myocardial Infarction
Current Vascular Pharmacology Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design Analysis of Parallel SVM Based Classification Technique on Healthcare using Big Data Management in Cloud Storage
Recent Patents on Computer Science Cyclooxygenase Inhibition and Atherothrombosis
Current Drug Targets Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Determination of Body Mass Index and Physical Activity in Normal Weight Children and Evaluation of Salivary Levels of Interleukin 10 and Interleukin 17
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)